The CHEK2 gene and inherited breast cancer susceptibility
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · cited 4×
“Most relevant to the topic of this review, CHEK2 emerges as a candidate tumor suppressor (Bartek and Lukas, 2003; Kastan and Bartek, 2004), and germline defects of CHEK2 predispose to familial breast cancer and some other types of malignancies, and somatic mutations of CHEK2 have been implicated in…”
BackgroundInfluentialDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 11×
“E-mail: heli.nevanlinna@hus.fi Oncogene (2006) 25, 5912–5919 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc of cells deficient in CHEK2 function.”
BackgroundInfluentialActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085 · cited 2×
“…breast cancer predisposing variant subvert the protein–protein interactions and cancel proper interactions of such CHEK2 protein with its substrates including BRCA1, p53 and Cdc25A, (Li et al., 2002; Falck et al., 2001a,b) while defects in the kinase domain inhibit the catalytic activity of CHEK2.”
BackgroundChecking on DNA damage in S phase
Bartek, J., Lukas, C., & Lukas, J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1493 · Cited by 758 · cited 1×
“…reflects the wide, and constantly broadening mediator role of CHEK2 in the signaling pathways that respond to DNA damage, with direct impact on downstream effectors within the cell cycle checkpoints, DNA repair and apoptosis machineries (Ahn et al., 2004; Bartek et al., 2004; Lukas et al., 2004).”
BackgroundDistinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage.
Lukas, C., Falck, J., Bartkova, J., Bartek, J., & Lukas, J. (2003) · Nature Cell Biology · doi:10.1038/ncb945 · Cited by 474 · cited 1×
“At least the initial, ATM-mediated phosphorylation of CHEK2 occurs exclusively at the sites of DNA damage, after which the activated CHEK2 rapidly moves throughout the nucleoplasm to spread the alert signal from damaged DNA and target its substrates (Lukas et al., 2003).”
BackgroundMammalian cell cycle checkpoints: signalling pathways and their organization in space and time
Lukas, J., Lukas, C., & Bartek, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.006 · Cited by 381
Concomitant inactivation of p53 and Chk2 in breast cancer
Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205207 · Cited by 91 · cited 3×
“…CHEK2 protein expression has been found absent or grossly reduced in tumors from carriers of the 1100delC germline mutation and also in other familial or sporadic breast tumors (Sullivan et al., 2002; Vahteristo et al., 2002; Oldenburg et al., 2003; Kilpivaara et al., 2004; Honrado et al., 2005).”
BackgroundMutation analysis of the CHK2gene in families with hereditary breast cancer
Allinen, M., Huusko, P., Mäntyniemi, S., Launonen, V, & Winqvist, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1858 · Cited by 85
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers
Ingvarsson, S., Sigbjornsdottir, B. I., Huiping, C., Hafsteinsdottir, S. H., Ragnarsson, G., Barkardottir, R. B., Arason, A., Egilsson, V., & Bergthorsson, J. T. (2002) · Breast Cancer Research · doi:10.1186/bcr435 · Cited by 63 · cited 2×
“Other, rare variants have been found in other studies as well (Ingvarsson et al., 2002; Sodha et al., 2002a; Schutte et al., 2003; Dufault et al., 2004).”
BackgroundResult
Cited by
Inherited Susceptibility to Common Cancers
Foulkes, W. D. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802968 · Cited by 563
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Plant flavonoids in cancer chemoprevention: role in genome stability
George, V. C., Dellaire, G., & Rupasinghe, H. P. V. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.007 · Cited by 362
Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5922 · Cited by 306
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Moschetta, M., George, A., Kaye, S. B., & Banerjee, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw142 · Cited by 292
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2251 · Cited by 288
ATM and ATR signaling at a glance
Awasthi, P., Foiani, M., & Kumar, A. (2015) · Journal of Cell Science · doi:10.1242/jcs.169730 · Cited by 271
Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
Vitale, I., Galluzzi, L., Vivet, S., Nanty, L., Dessen, P., Senovilla, L., Olaussen, K. A., Lazar, V., Prudhomme, M., Golsteyn, R. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001337 · Cited by 77
“The checkpoint kinase-1 (Chk1) is also lost in aggressive lymphoid tumors [20].”
BackgroundHereditary breast cancer: From molecular pathology to tailored therapies
Tan, D. S. P., Marchiò, C., & Reis-Filho, J. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.057950 · Cited by 60
YI, B.-R., CHOI, K. J., KIM, S. U., & CHOI, K.-C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1523 · Cited by 32
“The product of the cell cycle checkpoint kinase 2 (CHEK2) gene responds to DNA damage (doublestrand breaks) in a dynamic, multistep process and protects genomic integrity (58).”
Background
Metadata
- Authors
- Nevanlinna, H., & Bartek, J.
- Venue
- Oncogene
- Published
- 2006-09-25
- Volume
- 25
- Issue
- 43
- Pages
- 5912-5919
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2012718299
- Cited by
- 219
- References
- 10
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.